NicOx Announces U.S. Phase 2a Results For PF-03187207 And Gives An Update On Continuing NO-prostaglandin Program
NicOx S.A.
(Euronext Paris: COX) announced the results of a U.S. phase 2 study,
conducted by its partner Pfizer Inc, which compared the safety and efficacy
of various doses of PF-03187207 to Xalatan(R) (latanoprost) 0.005% in
patients with primary open-angle glaucoma and ocular hypertension. The
higher doses of PF-03187207 demonstrated a clinically significant reduction
in diurnal intraocular pressure (IOP) from baseline and the highest dose
showed consistently more IOP lowering than Xalatan(R) 0.005%, at all study
visits and at all individual time points, suggesting a beneficial effect of
nitric oxide donation. PF-03187207 is a nitric oxide-donating prostaglandin
analog, which is covered by the companies’ Generico cialis pillole senza ricetta August 2004 agreement.
On the primary endpoint at 28 days, PF-03187207 showed a 12%
improvement over Xalatan(R) 0.005% which did not reach statistical
significance. However, a statistically significant advantage over
Xalatan(R) 0.005% was observed on a number of secondary endpoints (pGenerico levitra pillole senza ricetta | comprare cialis soft mastercard | comprare generico cialis
Tags: capoten, hypertension